在阿尔茨海默病中的功能性大脑网络可控性功能障碍及其与认知和基因表达概况的关系
Chuchu Zheng1,2, Xiaoxia Xiao3, Wei Zhao1,2
1MOE-LCSM, School of Mathematics and Statistics, Hunan Normal University, Changsha 410006, People's Republic of China.
Journal of neural engineering
|March 19, 2024
概括
阿尔茨海默病 (AD) 患者表现出大脑网络控制能力的改变,在默认模式网络中控制能力降低,在边缘网络中控制能力增加. 这些变化与认知功能和基因表达相关,提供了对AD病变的洞察.
科学领域:
- 神经科学是一个神经科学.
- 网络科学 网络科学
- 遗传学 是一个遗传学.
背景情况:
- 网络控制理论越来越多地用于理解大脑状态过渡.
- 阿尔茨海默病 (AD) 对功能网络可控性的影响及其遗传基础尚未得到充分理解.
研究的目的:
- 为了比较AD患者和正常对照者 (NCs) 之间的功能网络可控性.
- 为了研究AD中改变的可控性和认知功能之间的关系.
- 为了确定与AD改变可控性相关的遗传机制.
主要方法:
- 在64名AD患者和64名NC患者中对功能网络可控性措施的比较分析.
- 可控性和认知得分之间的相关性分析 (例如,迷你精神状态检查).
- 与艾伦人类大脑地图集成,以将可控性与基因表达特征相关联.
主要成果:
- 在默认模式网络 (DMN) 中,AD患者的平均可控性降低,在边缘网络 (LIM) 中可控性增加.
- 患有AD的患者在LIM网络中表现出降低的模态可控性,在DMN中增加的模态可控性.
- Salience网络可控性与阿兹海默症患者的认知评分正相关.
- 可控性变化与转录组概况空间相关,识别的基因在相关途径中得到丰富.
结论:
- 阿尔茨海默病与大脑功能网络可控性的显著改变有关.
- 这些变化与认知功能和特定的基因表达模式有关.
- 研究结果提供了关于AD病原体和潜在治疗点的见解.
更多相关视频
09:01A Method for Investigating Age-related Differences in the Functional Connectivity of Cognitive Control Networks Associated with Dimensional Change Card Sort Performance
Published on: May 7, 2014
10.2K
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
14.9K
相关概念视频
Neural Regulation
39.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K
Alzheimer's Disease: Overview
475
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
475
Alzheimer's Disease: Treatment
186
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
186
